S
udden cardiac death is a major worldwide public health burden, with an estimated annual incidence ranging from 180 000 to 450 000 1 in the United States and as many as 3.7 million deaths globally. 2 The majority of these deaths are because of coronary artery disease among the elderly. 3 However, ≈2000 to 5000 young people between 1 and 35 years of age die suddenly each year in the United States. 4 For many of these sudden deaths in the young, a comprehensive medicolegal investigation, including a conventional autopsy examination, elucidates a clear cause of death. However, in ≤40% of these cases, gross and microscopic inspection of the heart and other organs fails to reveal a definite cardiac/noncardiac etiology, 5 and therefore these cases are categorized as autopsy-negative sudden unexplained death in the young (SUDY).
Potentially lethal and heritable cardiac channelopathies such as long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, and Brugada syndrome are typically associated with grossly and histologically normal hearts and may account for a significant portion of SUDY. Additionally, heritable cardiomyopathies, including hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and arrhythmogenic cardiomyopathy (ACM), may present with a mild structural phenotype that could escape detection at autopsy. Together these genetic heart diseases may be the underlying etiology for a significant percentage of SUDY cases.
Recently, guidelines for autopsy investigations of SUDY cases stipulate procurement and retention of tissue suitable for DNA extraction as a class I recommendation and advise that postmortem genetic testing (ie, the molecular autopsy) be considered as the new standard of care in the decedent's evaluation. [6] [7] [8] With ≥99 sudden death-susceptibility genes to date, postmortem genetic testing with whole-exome sequencing (WES) and targeted gene analysis represents a costand time-effective approach for performing the molecular autopsy. Although there is increasing evidence to support the use of a whole-exome molecular autopsy (WEMA), 5, [9] [10] [11] [12] [13] [14] [15] standardization of the procedure for characterizing putative pathogenic mutations is crucial to enable proper counseling of surviving family members and accurate publishing for scientific progress. Recently, the American College of Medical Genetics (ACMG) has provided guidelines for the interpretation of sequence variants, 16 which may be helpful in delineating the predicted pathogenicity of variants identified by WEMA in SUDY cases.
Here, we describe a cohort of 25 unrelated SUDY victims referred consecutively by the Office of the Medical Examiner, Cook County, Illinois. We performed a WEMA to determine the spectrum and prevalence of ultrarare, nonsynonymous variants (NSVs) within sudden death-susceptibility genes and demonstrate use of both the ACMG guidelines and the necropsy-derived phenotype data for proper variant adjudication.
METHODS
The data, analytical methods, and study materials will not be made available to other researchers for the purposes of reproducing the results or replicating the procedure.
Study Subjects
From January 2012 to December 2013, 25 consecutive, unrelated SUDY cases were referred to the Windland Smith Rice Sudden Death Genomics Laboratory at the Mayo Clinic in Rochester, Minnesota, to undergo WEMA after Mayo Clinic Institutional Review Board approval. All 25 cases underwent a comprehensive autopsy by the Office of the Medical Examiner from Cook County, Illinois. Enrollment criteria required sudden death of an individual between 1 and 40 years of age, which remained unexplained or equivocal after a comprehensive autopsy.
Control Population
A total of 973 European white control exomes (509 females, 464 males) from the ICR1000 UK exome series and the 1958 Birth Cohort study were included for a case:control subset analysis of genetic variation amid these 99 genes between white decedents and these controls. 17 As previously reported, exome sequencing was performed using the Illumina TruSeq and Illumina instruments.
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DNA Isolation
Genomic DNA was isolated from autopsy whole blood or frozen tissue using the Gentra Puregene Blood Kit (Qiagen) following the manufacturer's protocol.
Clinical Perspective
What Is New?
• The first population-based, case-series study involving the whole-exome sequencing-based cardiac channelopathy/cardiomyopathy gene-specific molecular autopsy of sudden unexplained death in the young cases within the United States.
What Are the Clinical Implications?
• Although the American College of Medical Genetics guidelines are useful, careful evaluation of the decedent's autopsy findings and premortem clinical phenotype remains critical before adjudicating a variant as the definitive cause of death.
• The goal of these investigative studies is to provide closure to families surrounding the loss of their loved one, but perhaps the only thing worse than no answer is to give a false answer prematurely. 
Variant Filtering and Pathogenicity Assessment
After WES, variants were filtered using Qiagen's Ingenuity Variant Analysis software (Qiagen Bioinformatics). Variants were included only if they (1) had a high-quality score (read depth >10 reads, call quality >20, genotype quality >20, and present in genes outside the top 1% of exonically variable genes and top 5% of exonically variable 100 base windows), (2) 19 and the National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project[n=6503] databases). Variants meeting these criteria underwent a further gene-specific surveillance for all known cardiac channelopathy-, cardiomyopathy-, and sudden unexplained death in epilepsy-susceptibility genes (N=99) (Table I in the online-only Data Supplement).
The ACMG guidelines for the interpretation of sequence variants were used to classify identified variants as pathogenic (P), likely pathogenic (LP), or variant of uncertain significance (VUS). 16 To be considered clinically actionable, the variant had to meet ACMG guideline criteria for a P or LP variant designation and be congruent with the presence/absence of disease-or gene-suggested autopsy findings. Herein we consider a clinically actionable variant as an LP or a P variant that should immediately prompt the physician to perform mutation-specific cascade genetic testing besides the standard cardiology clinical evaluation in all first-degree relatives of the deceased. Further, among those relatives who test positive for the implicated variant, periodic reassessment of potential disease manifestation related to the identified disease-susceptibility variant should be performed.
Candidate disease-causing variants identified through WEMA were confirmed in the decedents' genomic DNA using standard polymerase chain reaction and Sanger sequencing methods. Polymerase chain reaction primers, conditions, and sequencing methods are available on request.
Statistical Analysis
Fisher's exact tests were performed to determine statistical significance between 2 groups. A P<0.05 was considered to be significant.
RESULTS
SUDY Cohort
The demographics for the 25 SUDY cases are summarized in Table 1 . The average age at death was 27±5.7 years. There were 17 males (68%) and 8 (32%) females. Thirteen (52%) cases were white and 12 (48%) were black. Sixteen (64%) cases were autopsy negative and 9 (36%) cases had equivocal findings or inconclusive cardiac abnormalities, with 6 (24%) having equivocal findings for a possible cardiomyopathy. The 25 SUDY victims died during these circumstances: unwitnessed (10; 40%), sleep (9; 36%), nonspecific (3; 12%), and exertion or auditory trigger (3; 12%). Eleven (44%) SUDY cases had a personal history of either illicit drug use (24%) or mental illness (20%). A prior history of arrhythmia or syncope was noted in 2 (8%) cases. No cases had a known family history of arrhythmia, syncope, seizure, or cardiac arrest.
Yield of NSVs in Sudden DeathSusceptibility Genes
After WEMA, we identified 27 ultrarare (MAF <0.00005) NSVs within the 99 sudden death-susceptibility genes in 16/25 (64%) individuals overall, including 9/12 (75%) Values indicates n (%) or mean.
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black and 7/13 (54%) white decedents ( Figure 1 and Table 2 ). Compared with the 54% yield observed in white cases, ultrarare NSVs were identified in 281/973 (28.9%, P=0.064) European white controls ( Figure 2 ). It is interesting to note that 4/13 (30.8%) white SUD cases hosted multiple ultrarare NSVs amid these 99 genes versus 43/973 (4.4%, P=0.002) of the European controls ( Figure 2 ). Of the 27 NSVs identified, 4 (p.R783H-MYH7, p.L567Q-SCN5A, p.Y462S-RYR2, and p.N4763S-RYR2) were present in major genes (ie, strong evidence for disease association) for cardiac channelopathies and cardiomyopathies (KCNQ1, KCNH2, SCN5A, RYR2, MYH7, and MYBPC3) and 23 variants were in "minor" genes (ie, limited evidence genes) ( Table 2 and Figure 3 ). None of the variants was identified within any of the 3 sudden unexplained death in epilepsy-susceptibility genes (KCNA1, SCN1A, and SCN8A).
Variant Adjudication With ACMG Guidelines
Of the 27 ultrarare NSVs, 10 NSVs (37%) were classified as P variants or LP variants based on the ACMG guideline criteria ( Figure 1 and Figure 2 ). P or LP variants were identified in 5/16 (31%) autopsy-negative SUDY victims and in 2/6 (33%) SUDY victims who had an equivocal finding of cardiomyopathy at autopsy. Nine (36%) decedents hosted an ultrarare VUS. These VUSs are potentially informative given their ultrarare status. However, all 17 VUSs identified occurred in so-called minor genes where the strength of evidence for disease association is limited (Figure 3) . Furthermore, only 5 of the 17 VUSs matched the phenotype at autopsy. Although there appears to be genotype-phenotype concordance potentially, these variants could not be considered the underlying cause of death until further evidence for pathogenicity is satisfied with either functional validation studies or other criteria in the ACMG guidelines. Twelve VUSs were discordant with the phenotype observed at autopsy and therefore were dismissed as likely benign ( Figure 3 ).
Clinically Actionable Variants
The ACMG has proposed that the use of LP (and therefore also pathogenic) should mean that the variant of interest has a ≥90% certainty of being diseasecausing. 16 However, some NSVs identified through Shown is a bar graph indicating the percentage yield of ultrarare (minor allele frequency <0.005%) nonsynonymous variants and ACMG guideline-predicated pathogenic/likely pathogenic variants detected among 99 cardiac channelopathy/cardiomyopathy/SUDEP-associated genes for our overall cohort and the ethnic-specific (white or black), autopsy-negative, and autopsyequivocal subsets. ACMG indicates American College of Medical Genetics; and SUDEP, sudden unexplained death in epilepsy. Figure 3 ). The remaining 4 P/LP variants (p.Q1289X-DSP, p.K942X-MYH6, c.903+1 G>A-NEBL, and p.Y462S-RYR2) were not congruent (Table 2 and Figure 3) ORIGINAL RESEARCH ARTICLE guideline criteria for P or LP designation based on being an ultrarare and null variant (ie, nonsense or spliceerror), these variants in cardiomyopathy-associated genes were identified in SUDY victims, with no autopsy findings suggestive of a structurally abnormal heart. Therefore, these variants may require additional lines of evidence before assigning them as being diseasecausing and relevant to surviving family members. The p.Y462S-RYR2 variant was identified in a patient with autopsy findings consistent with HCM. RYR2 mutations cause catecholaminergic polymorphic ventricular tachycardia, a structurally normal heart-associated arrhythmia syndrome. This SUDY case also hosted a desmin (p.R350Q-DES) LP variant that would be consistent with his autopsy findings and most likely represents the pathogenic basis for the decedent's sudden death.
Case Summaries for SUDY Victims With a Clinically Actionable Variant
Overall, 4/25 (16%) of the SUDY cases hosted ≥1 clinically actionable variant. A 14-year-old white male (Case 1, Table 2 ) who experienced an exertion-related autopsy-negative sudden death hosted a p.L567Q-SCN5A P variant and a p.N4763S-RYR2 LP variant. SCN5A encodes a voltage-gated cardiac sodium channel, and mutations in the gene have been associated with LQT3 20 and Brugada syndrome 1. 21 Electrophysiological studies of the p.L567Q-SCN5A mutation have demonstrated a significant effect on sodium channel inactivation, 22 and the patients with this specific mutation are particularly prone to sudden death. 23 
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a structurally normal heart-associated arrhythmia syndrome that often manifests during exertion. A 27-year-old black female (Case 9, Table 2 ) who collapsed suddenly with seizure-like activity had a p.R783H-MYH7 P variant and a p.V27236fs-TTN LP variant. She had a history of a cardiac blood clot 4 years before death, and her autopsy was equivocal for ischemic cardiomyopathy. The MYH7 gene is associated with familial HCM and DCM. Although the p.R783H variant results in a conservative amino acid substitution, this specific variant has been observed previously in 2 individuals with cardiomyopathy. 24 TTN frameshift mutations have been associated with DCM. The TTN frame-shift variant identified in this SUDY case localizes to the sequence segment encoding for the A-band region of the protein, where such frameshift mutations are overrepresented in cases of DCM compared with controls.
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A 28-year-old white male (Case 15, Table 2) found dead in bed hosted both a p.R350Q-DES and p.Y462S-RYR2 LP variant. He had a history of arrhythmias and was scheduled for cardioversion later that year. Additionally, his autopsy was equivocal for HCM, with microscopic findings of myocyte hypertrophy and gross findings of an enlarged tricuspid valve with abnormal chordae, enlarged chambers, left ventricle hypertrophy, and fusion of right and noncoronary cusps of the aortic valve. His heart was enlarged, weighing 610 g. His mother was diagnosed previously with HCM. DES-encoded desmin is a class III intermediate filament specific to muscle cells. Mutations in desmin have been associated with HCM, DCM, myofibrillar myopathy, and sudden death. [26] [27] [28] [29] RYR2 encodes the cardiac ryanodine receptor found in the sarcoplasmic reticulum of cardiac muscle. The receptor facilitates calcium release that is crucial for cardiac contraction.
A 36-year-old white female (Case 23, Table 2 ) found unresponsive in bed hosted a p.D22167fs-TTN frameshift variant designated as LP. She had a history of heart murmur of unknown type. Although originally considered autopsy-negative, microscopic findings at autopsy included mild to moderate interstitial fibrosis as well as myocyte hypertrophy. The mutation results in a frameshift mutation within the region encoding for the A-band portion of the TTN protein where frame-shift mutations are overrepresented in DCM cases when compared with controls.
DISCUSSION
Since providing the first ever proof-of-principle case report of a WES-based comprehensive molecular autopsy of a previously healthy 16-year-old victim of SUDY , where we identified a pathogenic MYH7 mutation, 30 the utility of the WEMA has been increasingly recognized as an efficient and cost-effective method for comprehensive postmortem genetic evaluation of SUDY cases.
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Here, we present the first population-based study involving WEMA of SUDY cases within the United States. Using WES and a gene-specific analysis involving 99 cardiac channelopathy-, cardiomyopathy-, and sudden unexplained death in epilepsy-associated genes, we identified an ultrarare (MAF <0.00005; 1 in 20 000 alleles) amino acid-altering variant in a sudden deathsusceptibility gene in 54% of our white and 75% of our black victims of SUDY.
In 2016, Bagnall and colleagues 5 reported on the genetic analysis of 59 cardiac channelopathy/cardiomyopathy genes in a similar SUDY cohort of 113 cases from Australia or New Zealand. Using an MAF <0.1% (ie, 1 in 1000 alleles), 27% of their cases hosted what they termed a clinically relevant, pathogenic, or likely pathogenic cardiac gene mutation. Of the 36 clinically relevant variants identified, 30 had an MAF <0.00005 (the threshold used in our study). Thus, 6 of the variants identified would not have been considered to be potentially disease-causing using our more stringent MAF cutoff. In fact, 4 of these variants have a higher prevalence in Exome Aggregation Consortium (1 in 500 to 1 in 1000 subjects) than the estimated disease prevalence (eg, 1 in 2000 for long QT syndrome) with which they would be associated.
Although both studies support the utility of WEMA to identify potential sudden death-causing variants within sudden death-susceptibility genes, the challenge of the WES-based molecular autopsy does not lie in the identification of variants but, rather, in the adjudication of their predicted pathogenicity. Accurate variant classification is crucial to enable proper counseling of surviving family members and accurate publishing for scientific progress.
Erroneously or prematurely adjudicating ambiguous variants as pathogenic has the potential to harm patients and their families. Tragically, this became a reality for 1 family described by Ackerman et al 29 as they dealt with the disastrous consequences of unnecessary treatment based on an erroneously interpreted variant in KCNQ1. Our group and others have estimated previously that as much as 10% of the variants published as long QT syndrome-associated mutations may be classified incorrectly. 31, 32 This number is likely to be higher when accounting for all sudden death genes because a recent study has indicated that as many as 30% of all disease-causing genetic variants in the literature may have been reported incorrectly. 33 To assist in the interpretation of identified variants, the ACMG guidelines provide a framework for variant classification by incorporating a variety of weighted factors that lead to a final delineation of P, LP, benign, or VUS. 16 Using strict criteria, variants are assessed for very strong (ie, a null variant), strong (ie, the same amino acid change as a previously established pathogenic variant, confirmed as de novo when there is no family history, or is associated with well-established functional studies demonstrating a deleterious effect), moderate (ie, absence from large control populations like Exome Aggregation Consortium), or supporting (ie, multiple lines of computational evidence predicting a deleterious effect) evidence for pathogenicity. Points earned in each category are combined in a variety of ways to reach a final variant classification.
Recently, after interrogation of 77 cardiac channelopathy/cardiomyopathy genes, Lahrouchi and colleagues 15 reported a yield of ACMG guideline-predicated P/LP variants in 13% of their mostly European decent (88%) cohort of 302 SUDY cases without structural heart disease or nonspecific cardiovascular changes. Congruent with a phenotype of negative-autopsy and suspected sudden cardiac arrhythmia death, 85% of the L/LP variants identified by Lahrouchi and colleagues 15 were in major cardiac channelopathy-susceptibility genes (ie, KCNQ1, KCNH2, SCN5A, and RYR2).
While using their own interpretation for labeling variants as P or LP, Bagnall and colleagues 5 reported finding such variants in 27% of their SUDY cases. However, when applying the ACMG guideline criteria to their identified variants, this yield decreases to only 7.1% (8/113). In fact, based on the ACMG guidelines, 28 of their 36 P or LP variants would be demoted to a VUS. The difference in variant interpretation stems largely from the overcalling of missense variants as being LP. In their study, missense variants with an MAF <0.1% that were predicted to be damaging by ≥2 out of 3 in silico tools (SIFT, Polyphen, Mutation Taster) and involving conserved nucleotides (genomic evolutionary rate profiling score ≥2) were considered as LP. 5 However, according to ACMG, this level of evidence alone would be deemed insufficient to promote a variant to an LP designation.
Based on ACMG guideline criteria, 28% of our overall cohort hosted ≥1 P/LP variant. The yield of P/LP variants was ≈30% for both the autopsy-negative and equivocal cases with cardiomyopathic findings at autopsy. This reflects a 20% higher yield of ACMG guideline-predicated variants in our cohort than what was observed in the phenotypically and demographically similar cohort investigated by Bagnall and colleagues. 5 The large difference in yield may stem from differences in the next-generation sequencing platforms and bioinformatics-based variant annotation and analytic pipelines that were used, as well as our inclusion of 40 additional genes that were not included in the Bagnall study. 5 In fact, 3 of our 25 (12%) cases had either a TTN frameshift (2 cases) or NEBL splice-error (1 case) LP variant. However, these 2 genes were not included in the Bagnall study. 5 Although 28% of our SUDY cases hosted a P or an LP variant based on the ACMG guidelines, the decedent's phenotype at autopsy was congruent with the genetic finding in only 14% of cases and therefore considered clinically actionable. These clinically actionable P/LP variants have sufficient genotype-phenotype evidence to warrant cascade genetic testing of surviving family members. However, other ultrarare variants that do not rise to our present consideration of clinically actionable might be deemed as nevertheless worthy of careful research/clinical-based investigations to see whether the variant cosegregates with the disease phenotype. If it did, then those variants might be elevated to a clinically actionable status that would warrant cascade genetic testing for future family members.
It is interesting to note that 3 cardiomyopathy-associated genes variants that satisfied the ACMG guideline criteria for P or LP designation based on being an ultrarare and null variant (ie, nonsense or splice-error) were identified in victims of SUDY with no autopsy findings suggestive of a structurally abnormal heart. Although some cardiomyopathy-associated gene variants can provide a potentially lethal arrhythmic substrate before the development of overt cardiomyopathic changes, because these identified variants were not congruent with the observed phenotype, the designation of these variants as ACMG guideline-predicated P or LP should be rendered with some residual skepticism.
It is noteworthy that one-third of the ultrarare variants identified were categorized as needs further functional study. These variants are potentially informative clinically given their presence in disease-associated genes and their ultrarare status. However, they currently lack sufficient clinical evidence (ie, cosegregation with disease phenotype) and research-based evidence (ie, in vitro functional validation assay) to be put forward as a disease-causing, clinically relevant variant.
CONCLUSIONS
Despite 64% of this population-based cohort of consecutive, unrelated SUDY cases having ultrarare, nonsynonymous variants within sudden death-susceptibility genes, 28% had a variant classified as either P or LP based on the ACMG guidelines. Furthermore, 14% of cases had a congruent genotype-phenotype correlation enabling the variant to be clinically actionable for cascade genetic testing of surviving family members. The substantial number of VUSs demonstrates the necessity for further standardizing the adjudication of putative pathogenic variants. Although the current ACMG guidelines are useful, careful evaluation of the decedent's autopsy findings and premortem clinical phenotype remains critical before adjudicating a variant as the definitive cause of death in SUDY cases. The goal of
